Evidence map›Paper›PMID 40661523›Full record

ArticlebioRxiv : the preprint server for biology2025

A glycan atlas of the mammalian intestine through ontogeny and inflammation.

Steven J Siegel, Daniel Pomerantz, Jamie Heimburg-Molinaro, Shaikh Danish Mahmood, Joshua R Korzenik, Richard D Cummings, Seth Rakoff-Nahoum

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Steven J SiegelDivision of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.ORCID 0000-0003-0690-2390
Daniel PomerantzDivision of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.
Jamie Heimburg-MolinaroDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Shaikh Danish MahmoodDivision of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA, United States.
Joshua R KorzenikDivision of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA, United States.
Richard D CummingsDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Seth Rakoff-NahoumDivision of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.

Funding

Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1M
TRAINING GRANT IN GENETICST32GM007748 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Anne O'Donnell-Luria, Louise Wilkins-Haug · 1985 to 2026
$12.0M
Protein-Glycan Interaction Resource at the National Center for Functional Glycomics (NCFG)R24GM137763 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI RICHARD D CUMMINGS · 2020 to 2026
$5.8M
Immunological and Microbial Mechanisms in Food AllergyR01AI126915 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Talal Amine Chatila, Seth Rakoff-Nahoum · 2017 to 2026
$4.9M
Programmable benchtop bioreactors for scalable eco-evolutionary dynamics of the human microbiomeR01AI171100 · NIAID · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI KHALIL, AHMAD SAMIR, RAKOFF-NAHOUM, SETH · 2022 to 2025
$4.1M
Targeting microbial dysbiosis in Food Allergy to restore toleranceR01AI158814 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI CHATILA, TALAL AMINE, RAKOFF-NAHOUM, SETH · 2021 to 2025
$3.0M
Positive Selection as a Host Mechanism to Control the MicrobiomeDP2GM136652 · NIGMS · BOSTON CHILDREN'S HOSPITAL · PI RAKOFF-NAHOUM, SETH · 2019 to 2019
$2.7M
Leveraging glycan-metabolite interactions to shape structure and function of the gut microbiomeR01DK138023 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI Seth Rakoff-Nahoum · 2024 to 2026
$2.0M
Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey SystemR01GM140201 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CUMMINGS, RICHARD D · 2021 to 2023
$1.5M
Pediatric Infectious Diseases Research TrainingT32AI155391 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI KIM, DENNIS H, WESSELS, MICHAEL R · 2021 to 2025
$1.3M
Carbohydrate Public Good Interactions in Healthy and Dysbiotic Bacteroidales CommunitiesK08AI130392 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI RAKOFF-NAHOUM, SETH · 2017 to 2021
$905k
NIAID NIH HHS K08 AI130392NIAID NIH HHS R01 AI126915NIAID NIH HHS R01 AI158814NIAID NIH HHS R01 AI171100NIAID NIH HHS T32 AI155391NICHD NIH HHS K12 HD000850NIDDK NIH HHS R01 DK138023NIGMS NIH HHS DP2 GM136652NIGMS NIH HHS R01 GM140201NIGMS NIH HHS R24 GM137763NIGMS NIH HHS T32 GM007748
6 · The paper itself

Abstract

The muco-epithelial interface in the mammalian gut is composed of a mucus and epithelial lining fundamental to barrier function, microbe-host interactions, and intestinal homeostasis. This barrier is heavily glycosylated by O-linked sugars covalently linked to mucin glycoproteins, and N-linked sugars that coat epithelial surface proteins. Gut O- and N-glycans are thought to play central roles in barrier function, host defense, nutrition and attachment for commensals and pathogens, immunoregulation and cell-cell interactions. However, the precise nature of the glycans and how glycan composition changes through development, as a function of diet, and during inflammation, remains incompletely understood. Here, we apply O- and N-glycomic platforms to profile glycans on mucus and intestinal epithelium. By mapping individual glycan species spatially and temporally we identify 57 O- and 18 N-glycans in the mouse intestine, and observe that fucosylation and sialylation varies according to intestinal region and developmental stage. We identify a subset of glycans regulated by the gut microbiome, and observe a constriction of the glycan repertoire during inflammation in both mice and humans. Together, these results provide an atlas of individual intestinal glycans and their dynamic range through ontogeny and inflammation, and represent a significant resource for our understanding of the role of intestinal glycans in health and disease and glycan-focused therapies for intestinal inflammation and shaping the gut microbiome.

Identifiers

PMID40661523
PMCPMC12258701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.